Vanda Pharmaceuticals CEO Mihael Polymeropoulos' 2018 pay rises 13% to $4.3M
Vanda Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 25, 2019
Vanda Pharmaceuticals reported fiscal year 2018 executive compensation information on April 25, 2019.
In 2018, five executives at Vanda Pharmaceuticals received on average a compensation package of $2.8M, a 21% increase compared to previous year.
Average pay of disclosed executives at Vanda Pharmaceuticals
Mihael H. Polymeropoulos, Chief Executive Officer, received $4.3M in total, which increased by 13% compared to 2017. 38% of Polymeropoulos' compensation, or $1.6M, was in option awards. Polymeropoulos also received $700K in non-equity incentive plan, $700K in salary, $1.2M in stock awards, as well as $37K in other compensation.
Timothy Williams, General Counsel, received a compensation package of $3.4M. 55% of the compensation package, or $1.9M, was in option awards.
Gian Piero Reverberi, Senior Vice President, Chief Commercial Officer, earned $2.3M in 2018, a 10% increase compared to previous year.
James P. Kelly, Chief Financial Officer, received $2.2M in 2018, which decreases by 3% compared to 2017.
Gunther Birznieks, Senior Vice President, Business Development, earned $2M in 2018, a 10% increase compared to previous year.
Related executives
Mihael Polymeropoulos
Vanda Pharmaceuticals
Chief Executive Officer
James Kelly
Vanda Pharmaceuticals
Chief Financial Officer
Gian Reverberi
Vanda Pharmaceuticals
Former Senior Vice President, Chief Commercial Officer
Timothy Williams
Vanda Pharmaceuticals
General Counsel
Gunther Birznieks
Vanda Pharmaceuticals
Senior Vice President, Business Development
You may also like
Source: SEC filing on April 25, 2019.